Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

TheMotleyFool

0 0

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

Danish pharmaceutical giant, Novo Nordisk (NYSE: NVO) made a lot of headlines recently with a big buyout offer for Dicerna Pharmaceuticals (NASDAQ: DRNA). Novo Nordisk offered Dicerna shareholders a great big 80% premium, leading investors to wonder which biotech stock might be next.

For good reasons, Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a prime candidate for the next big biotech buyout. Here are four of the most important ones.

Image source: Getty Images.

Source Fool.com

Like: 0

ARWR

Share